UPDATE: Deutsche Bank Downgrades Sarepta Therapeutics Following FDA Announcement That NDA Filing is Premature

In a report published late Tuesday, Deutsche Bank analyst Robyn Karnauskas downgraded the rating on Sarepta Therapeutics (NASDAQ: SRPT ) from Buy to Hold, and lowered the price target from $71.00 to $17.00. In the report, Deutsche Bank noted, “Sarepta announced that the FDA now says NDA filing is premature